Please provide your email address to receive an email when new articles are posted on . A single treatment with preoperative intravesical electromotive instillation of mitomycin-C decreased the risk ...

In a recent randomized trial, electromotive intravesical administration of mitomycin before transurethral resection was shown to be effective in the prevention of bladder cancer recurrence. Although ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

The PDUFA target date was set for June 13, 2025. The Food and Drug Administration (FDA) announced that it has accepted the New Drug Application (NDA) for UGN-102 for intravesical solution for the ...

Most systemic anticancer regimens combine drugs for increased efficacy, but this approach has rarely been applied to intravesicular treatment of bladder cancer. The current standard treatment for ...

WASHINGTON -- An investigational non-surgical treatment led to a "robust" complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

In a small case series of high-risk nonmuscle-invasive bladder cancer, sequential BCG and mitomycin C, cystectomy was avoided in most cases. Sequential use of bacillus Calmette-Güerin (BCG) and ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...

Instilling mitomycin C within 24 hours of TURBT vs after 2 weeks was associated with a 27% lower risk of recurrence. For non-muscle-invasive bladder cancer (NMIBC) patients undergoing transurethral ...

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial This study aimed to ...

Despite current treatment after transurethral resection of a bladder tumor, recurrences and progression remain a problem. Keyhole limpet hemocyanin (KLH) was beneficial in earlier studies. In this ...